A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness

NCT04634409 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

1755

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

DRUG: Bamlanivimab
DRUG: Etesevimab
DRUG: Placebo
DRUG: VIR-7831
DRUG: Bebtelovimab

Sponsor

Eli Lilly and Company

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]